Replies to post #473436 on NorthWest Biotherapeutics Inc (NWBO)

[Mionaer1]

I emailed the report to NWBO and made known my displeasure with their public relations.
Maybe that makes more sense.

[dmb2]

Very well done, agreed all of us should do the same, thx!

[Kap10jak]

It makes you wonder if maybe a little extra cash in the right places could cause NWBO's journal publication to be delayed and others to misrepresent results while NWBO must remain silent. Also this a real kick in the face to LL and many other doctors.

[pairofoldsocks]

I also emailed AACR and told them they need to fire whoever wrote the update.

[Troymister]

Excellent move.

[bjoel5150]

Biosec- sorry I don’t have private messaging

I sent the email to: [e-mail]

[Horseb4CarT]

Please post how you sent your email, their email address?

I don’t usually go this far, but I think it’s important for such potentially tragic misreporting be corrected, and therefore will add my voice.

[ATLnsider]

Here is the email address to write to AACR Cancer Discovery:

[e-mail]

[Cheesey12]

Emails like this will carry more weight once the clinical trials.gov is updated with the new endpoints. I too will send an email to them this weeks with the link to clinicaltirls.gov website once it is updated.

[Magrit]

Sent this just now to AACR:

[e-mail]

Article correction for DC-Vax L

At New York Academy of Sciences on May 10, 2022 there was a scientific presentation of DC-Vax L which is a novel immunotherapy for GBM which basically takes the patient’s own cancer cells to train the immune system to attack the cancer. DC-Vax L showed amazing results above the current standard of care for overall survival and should line up for regulatory approval by the FDA. Both the primary and secondary endpoints for overall survival inn new and recurrent GBM patients were statistically significant.

Below is a link to the Phase III trial results. Please have your article rewritten yesterday to reflect the positive results of DC-Vax L as well as a retraction of the incorrect statistics included in your article. The article reflects an incorrect data analysis. I would suggest talking to Dr. Mulholland or Dr. Liau to confirm the accurate results as well as the information provided that progression free survival (pfs) is no longer an effective assessment with regards to GBM trials.

This company is also working on a cancer platform to treat a broad variety of cancers in the future. Northwest Biotherapeutics is trying to bring effective cancer treatments to the world and this is news worthy.

Do you want to be part of the problem and stock price manipulation or do you want to report the truth?

Thank you for your time in reviewing the data, correcting the article and publishing a retraction.

Margaret Monson

https://virtualtrials.org/dcvax/dcvax.pdf